Risk of hospitalization with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes lacking evidence of chronic kidney disease: Real-world data

Meir Schechter, Cheli Melzer Cohen, Tamir Zelter, Ilan Yanuv, Aliza Rozenberg, Gabriel Chodick, Avraham Karasik, Ofri Mosenzon*

*Corresponding author for this work

Research output: Contribution to journalLetterpeer-review

Original languageEnglish
Pages (from-to)3054-3058
Number of pages5
JournalDiabetes, Obesity and Metabolism
Issue number10
StatePublished - Oct 2023

Cite this